Geron - GERN Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GERN shares.
View GERN analyst ratings or view top-rated stocks.

4 equities research analysts have issued twelve-month price objectives for Geron's stock. Their GERN share price forecasts range from $4.00 to $7.00. On average, they anticipate the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 66.7% from the stock's current price.
View analysts price targets for GERN or view top-rated stocks among Wall Street analysts.

Geron's stock was trading at $2.42 on January 1st, 2023. Since then, GERN stock has increased by 36.4% and is now trading at $3.30.
View the best growth stocks for 2023 here.

Geron saw a drop in short interest during the month of January. As of January 15th, there was short interest totaling 22,710,000 shares, a drop of 22.2% from the December 31st total of 29,190,000 shares. Based on an average daily trading volume, of 8,130,000 shares, the days-to-cover ratio is currently 2.8 days.
View Geron's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our GERN earnings forecast.

Geron Co. (NASDAQ:GERN) released its earnings results on Thursday, November, 3rd. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. The biopharmaceutical company earned $0.30 million during the quarter, compared to analysts' expectations of $0.12 million. Geron had a negative net margin of 8,563.80% and a negative trailing twelve-month return on equity of 110.76%.

5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), Organigram (OGI), SCYNEXIS (SCYX) and Bionano Genomics (BNGO).

Geron trades on the NASDAQ under the ticker symbol "GERN."

Geron's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Douglas Lane & Associates LLC (0.02%), Allspring Global Investments Holdings LLC (0.01%), Private Advisor Group LLC (0.01%), Kestra Advisory Services LLC (0.01%), Wedbush Securities Inc. (0.01%) and Tennessee Valley Asset Management Partners (0.00%).
View institutional ownership trends.

Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GERN stock can currently be purchased for approximately $3.30.

Geron (NASDAQ:GERN) has a market capitalization of $1.26 billion and generates $1.39 million in revenue each year. The biopharmaceutical company earns $-116,110,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

Geron's mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The official website for the company is www.geron.com. The biopharmaceutical company can be reached via phone at (650) 473-7700, via email at investor@geron.com, or via fax at 650-473-7750.